- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02269787
TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Annually, about 25,000 Veterans receive inpatient detoxification (detox) for substance use disorders (SUDs). Detox is not SUD treatment; it is the medical management of withdrawal to prevent complications, which may be fatal. Detox inpatients who enter SUD treatment and peer-based mutual-help groups (e.g., Alcoholics Anonymous) have much better outcomes (less substance use, HIV/HCV risk behaviors, homelessness, rehospitalizations, Emergency Department visits) than those who do not. However, because of their unique characteristics (severe and chronic addictions, co-morbidities, lack of resources, self- and provider-perceptions as unsuitable for treatment), most Veterans discharged from inpatient detox do not enter SUD treatment. For many Veterans, a pattern of repeated inpatient detox, with each episode incurring a higher risk of overdose, occurs. Therefore, in its Uniform Services Handbook, Mental Health Operations places major emphasis on increasing the rate of SUD treatment initiation and engagement following detox to benefit Veterans' outcomes and prevent more use of costly health care.
The primary objective of this project is to implement and evaluate Enhanced Telephone Monitoring (ETM) as a new and innovative telehealth intervention to facilitate the transition from inpatient detox to SUD specialty treatment (residential, outpatient, pharmacotherapy), thereby improving Veterans' outcomes and decreasing VA health care costs. In a randomized trial at two sites (VA Palo Alto and Boston), investigators hypothesize that patients receiving ETM, compared to patients in usual care (UC), will be more likely to enter and engage in SUD treatment and mutual-help, have better SUD and related outcomes, and have fewer and delayed acute care episodes. This project will also conduct a formative evaluation of how to implement ETM VA-wide, focusing on diverse subgroups of Veterans. Further, it will conduct a Budget Impact Analysis (BIA) to determine the impact of ETM on total costs of VA care. Investigators hypothesize that the higher costs associated with ETM (because patients will engage in SUD treatment) will be more than offset by its lower costs of acute care.
Patients in the ETM condition will receive an in-person session while in detox, followed by coaching over the telephone for 3 months after discharge. The intervention will incorporate Motivational Interviewing, and Contracting, Prompting, and Reinforcing, to provide support while waiting for treatment, and facilitate entry into treatment and mutual-help, and improved responses to crises. Patients will be assessed at baseline and 3 and 6 months post-discharge for outcomes and non-VA health care; VA health care will be assessed with VA databases. GLMM analyses will be conducted to compare the UC and ETM groups on course of outcomes over time. The formative evaluation to inform the implementation of ETM will use the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework. Semi-structured interviews will be conducted with inpatient detox staff and patients to yield facilitators of ETM implementation and modifiable barriers with associated action plans. For the BIA, costs of ETM will be measured through microcosting methods. For patients in both the ETM and UC groups, all inpatient, residential, outpatient, and pharmacy care will be measured from VA utilization and cost files.
In summary, Mental Health Operations is committed to eradicating the dangerous, costly pattern of Veterans obtaining inpatient detox services but not receiving the SUD treatment they need. Telehealth interventions, a promising way to improve treatment access and outcomes by SUD patients, have not been utilized with the challenging population of detox inpatients before. In accordance with others in this CREATE, this project will help to accomplish Mental Health Operations' goal of implementing the Uniform Handbook by increasing Veterans' access to, engagement in, and benefit from, SUD treatment services, particularly among Veterans who are using VA medical services and need SUD services but are not receiving them.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Palo Alto, California, Verenigde Staten, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Beginning an episode of inpatient detoxification at the Boston or Palo Alto Veterans Affairs medical facilities, and
- have ongoing access to cell phone or land line telephone
Exclusion Criteria:
- Significant cognitive impairment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Enhanced Telephone Monitoring
Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
|
Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
Andere namen:
|
Geen tussenkomst: Usual Care
Patients in the usual care condition will receive the care they would receive in the absence of a research project.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percent of Participants Who Had an Additional Inpatient Detoxification
Tijdsspanne: 6-month follow-up
|
Percent that had (yes) an additional inpatient detoxification 6 months following baseline assessment- additional inpatient detoxification was dichotomous, yes or no.
|
6-month follow-up
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Christine Timko, PhD, VA Palo Alto Health Care System, Palo Alto, CA
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CRE 12-010
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gebruikelijke zorg
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaWervingCAR-T-therapie ComplicatiesItalië
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHWervingDoor de patiënt gerapporteerde uitkomstmaten | CAR T-celtherapieZwitserland
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesWervingIn aanmerking komende hematopathologie of CAR-t-celbehandelingFrankrijk
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Nog niet aan het wervenAllogeen, CAR-T, eiwitvastlegging, niet-gen-bewerktChina
-
Shanghai International Medical CenterOnbekendGeavanceerde vaste tumor | PD-1 antilichaam | CAR-T-cellenChina
-
Ningbo Cancer HospitalOnbekendGeavanceerde maligniteiten | PD-1 antilichaam | CAR-T-cellenChina
-
Ruijin HospitalWerving
-
Shanghai General Hospital, Shanghai Jiao Tong University...WervingCAR-T-cel | Ph Positief ALLES | DasatinibChina
-
Massachusetts General HospitalActief, niet wervendHematologische maligniteit | CAR-T celtherapieVerenigde Staten
-
Zhongda HospitalWervingKlinische studie van op TCR-achtige CAR-T-cellen gerichte MSLN bij de behandeling van eierstokkankerVeiligheid en werkzaamheid van TCR-achtige CAR-TChina
Klinische onderzoeken op Enhanced Telephone Monitoring
-
International Food Policy Research InstituteHelen Keller International; Foreign Affairs, Trade and Development, CanadaVoltooidBloedarmoede | GroeivertragingBurkina Faso
-
Nottingham University Hospitals NHS TrustVoltooidHoofd-hals plaveiselcelcarcinoomVerenigd Koninkrijk
-
Miach OrthopaedicsActief, niet wervendVoorste kruisbandruptuur | Voorste kruisbandletselVerenigde Staten
-
Mayo ClinicSnap40 Ltd.VoltooidOp afstand monitorenVerenigde Staten
-
Kerry KuehlWervingBeroepsmatige spanning | Geestelijke gezondheid Welzijn 1 | Gezondheidsgedrag | Veiligheid problemenVerenigde Staten
-
Rush University Medical CenterUniversity of Illinois at Chicago; Michigan State UniversityActief, niet wervendFysieke activiteitVerenigde Staten
-
Kuopio University HospitalWervingHartoperatieFinland
-
American College of RadiologyGE Healthcare; Breast Cancer Research FoundationWervingBorstkankerVerenigde Staten
-
University of California, San DiegoNational Institute of Mental Health (NIMH); Kaiser PermanenteAanmelden op uitnodigingAutisme Spectrum Stoornis | Mentale gezondheid | Implementatie Wetenschap | GedragsgezondheidVerenigde Staten
-
VA Office of Research and DevelopmentActief, niet wervendArtrose van de knieVerenigde Staten